Skip to main content

Table 2 Univariate analysis of possible prognostic factors for progression free survival

From: Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors

Variable

Hazard ratio (95%CI)

P value

Sex

 Female

 Male

1

1.2 (0.8–1.9)

0.46

Diagnosis

 FNA

 FA

1

0.9 (0.5–1.6)

0.64

Age start CTx

  < 60

  ≥ 60

1

1.1 (0.7–1.7)

0.73

Grading

 G1

 G2

1

1.7 (0.98–2.9)

0.058

Ki-67

  ≤ 10 %

  > 10 %

1

1.1 (0.6–2.1)

0.76

Metastases

 Liver only

 Liver and others

1

1.0 (0.7–1.6)

0.91

Response (RECIST)

 No

 Yes

1

0.3 (0.18–0.56)

0.000*

Biochemical response

 No

 Yes

1

0.5 (0.3–0.9)

0.019*

Primary

 Non-pancreatic

 Pancreatic

1

0.8 (0.5–1.4)

0.51

Prior therapy

 No CTx

 CTx

1

0.8 (0.4–1.5)

0.41

Prior therapy

 SSA/IFN

 Others

1

0.9 (0.5–1.4)

0.61

  1. *significant differences; CI confidence interval, FNA functional non active, FA functional active, CTx chemotherapy, SSA somatostatin analogue, IFN interferon
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us